CEMENTIC, Paris, France; Laboratoire des Multimatériaux et Interfaces, Université Claude Bernard Lyon 1, Villeurbanne, France.
Hôpital quinze-vingt, Paris, France.
J Endod. 2024 Aug;50(8):1134-1142. doi: 10.1016/j.joen.2024.04.012. Epub 2024 May 6.
This study aimed to assess BioRoot RCS (BR) incorporating liposomal chlorhexidine digluconate (CHX) for its antibacterial activity, drug release capacity, and physicochemical properties.
Drug release of CHX liposomal formulations in combination with BR was evaluated spectrophotometrically and through mathematical release models for 30 days. A selected combination was evaluated for antimicrobial properties against Enterococcus faecalis biofilm growth on human dentin. Cytotoxicity was assessed following the ISO 10993-5:2019 standard on days 1, 3, and 7. Physicochemical properties were evaluated through setting time, Fourier transform infrared spectroscopy, solubility, contact angle, and film thickness.
From BR, liposomal CHX released up to 7-fold higher CHX than CHX solution (P < .05), following a triphasic drug release pattern compared to the CHX solution, which followed a quasi-Fickian diffusion. BR combined with a selected liposomal CHX completely inhibited E. faecalis biofilm growth compared to the combination of BR with CHX solution and the control group (P < .05). Liposomal CHX decreased the contact angle (P < .05) and solubility but increased cytotoxicity (P < .05) of BR, staying above the ISO threshold. None of the other physicochemical characteristics tested differed from BR (P > .05).
This liposomal formulation improved CHX release from BR, enhancing the antibacterial effectiveness. It presents a promising approach for local antibiofilm therapy in endodontics without substantially altering the physicochemical characteristics of BR.
本研究旨在评估 BioRoot RCS(BR)结合载氯己定双葡萄糖酸盐(CHX)的抗菌活性、药物释放能力和理化性能。
通过分光光度法和数学释放模型评估 CHX 脂质体配方与 BR 联合使用的 CHX 释放情况,为期 30 天。评估选定组合对人牙本质上粪肠球菌生物膜生长的抗菌性能。根据 ISO 10993-5:2019 标准,在第 1、3 和 7 天评估细胞毒性。通过凝固时间、傅里叶变换红外光谱、溶解度、接触角和薄膜厚度评估理化性能。
与 CHX 溶液相比,BR 从脂质体 CHX 中释放的 CHX 高达 7 倍(P <.05),呈现出三相药物释放模式,而 CHX 溶液则遵循拟 Fickian 扩散。与 BR 与 CHX 溶液的组合和对照组相比,BR 与选定的脂质体 CHX 联合使用完全抑制粪肠球菌生物膜的生长(P <.05)。脂质体 CHX 降低了接触角(P <.05)和溶解度,但增加了 BR 的细胞毒性(P <.05),保持在 ISO 阈值以上。未测试的其他理化特性与 BR 无差异(P >.05)。
这种脂质体制剂提高了 BR 中 CHX 的释放,增强了抗菌效果。它为牙髓内局部抗生物膜治疗提供了一种有前途的方法,而不会实质上改变 BR 的理化特性。